- Home
- IAE vs HOWL Comparison
IAE vs HOWL Comparison
Compare IAE & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IAE
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | IAE | HOWL |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 64.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IAE | HOWL |
|---|---|---|
| Price | $7.31 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 46.3K | ★ 517.1K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.31 | $0.60 |
| 52 Week High | $6.45 | $2.38 |
Technical Indicators
Market Signals| Indicator | IAE | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 51.50 |
| Support Level | $7.20 | $0.96 |
| Resistance Level | $7.35 | $1.03 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 51.13 | 93.10 |
Price Performance
Historical ComparisonAbout IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.